Phase 2 Ovarian Cancer Trial, RecruitingNCT07059845Sponsor: AbbVieCondition: Ovarian Cancer
Printed from Voxsanity (voxsanity.com.au) — NCT07059845 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
voxsanity.com.au ·
Eligibility summary from public government registries ·
18 August 2026 ·
not medical advice
Who may and may not be able to join
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who may be able to join
All parts of the trial require:
You must be willing to provide a stored tumor tissue sample or agree to a new tumor biopsy (using a low-risk, routine procedure) so that the tumor can be tested for a specific protein called FRα — and at least half of your tumor cells must show a strong enough level of this protein.
You must be generally well enough to carry out light activity and care for yourself (your doctor will assess this using a standard scale — scoring 0 or 1 out of 4).
Part 1 (Substudy 1) also requires:
If starting first-line treatment: you must have a confirmed diagnosis of advanced (Stage III or IV) high-grade serous ovarian, primary peritoneal, or fallopian tube cancer.
If starting second-line treatment: your cancer must be the platinum-sensitive type, meaning it came back more than 6 months after your last platinum-based chemotherapy ended.
You must have an available genetic test result showing whether your cancer has certain gene changes (BRCA or HRD status) — your doctor can explain what this means for you.
Parts 2 and 3 (Substudies 2 & 3) also require:
You must have a confirmed diagnosis of high-grade serous ovarian, primary peritoneal, or fallopian tube cancer.
Your cancer must have come back after 1 or 2 previous rounds of platinum-based chemotherapy.
Your cancer must be the platinum-sensitive type, meaning it returned more than 6 months after your last platinum-based chemotherapy ended.
Your cancer must be measurable on a scan at the time of joining the trial.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
Part 1 (Substudy 1):
Your cancer got worse while on, or shortly after finishing, your most recent triple-drug treatment course (before joining the trial).
You received an extra dose of a drug called bevacizumab after your last treatment cycle and before joining the trial.
You have previously been treated with a drug called mirvetuximab soravtansine, any other treatment that targets the FRα protein, or a type of drug known as a PARP inhibitor.
Parts 2 and 3 (Substudies 2 & 3):
You have received more than 2 separate courses ("lines") of chemotherapy in the past (confirm with trial site for how your specific treatments are counted, as maintenance therapies and some combined treatments may be counted differently).
You have previously been treated with mirvetuximab soravtansine or any other treatment that targets the FRα protein.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
St. George Private Hospital /ID# 276570, Kogarah, New South Wales
Chris O'Brien Lifehouse /ID# 276337, Sydney, New South Wales
Icon Cancer Centre Wesley /ID# 277199, Auchenflower, Queensland
Burnside War Memorial Hospital /ID# 277602, Adelaide, South Australia
Icon Cancer Centre Hobart /ID# 277688, Hobart, Tasmania
Monash Health - Monash Medical Centre - Clayton /ID# 276984, Clayton, Victoria
Barwon Health /ID# 277297, Geelong, Victoria
Austin Hospital /ID# 276534, Melbourne, Victoria
Epworth Hospital - Richmond /ID# 276347, Richmond, Victoria
St. John Of God Subiaco Hospital /ID# 277174, Subiaco, Western Australia
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT07059845
Sponsor: AbbVie
Phase: Phase 2
Status: Recruiting
Condition: Ovarian Cancer
Trial contact: 844-663-3742
More information: https://clinicaltrials.gov/study/NCT07059845
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who may be able to join
All parts of the trial require:
You must be willing to provide a stored tumor tissue sample or agree to a new tumor biopsy (using a low-risk, routine procedure) so that the tumor can be tested for a specific protein called FRα — and at least half of your tumor cells must show a strong enough level of this protein.
You must be generally well enough to carry out light activity and care for yourself (your doctor will assess this using a standard scale — scoring 0 or 1 out of 4).
Part 1 (Substudy 1) also requires:
If starting first-line treatment: you must have a confirmed diagnosis of advanced (Stage III or IV) high-grade serous ovarian, primary peritoneal, or fallopian tube cancer.
If starting second-line treatment: your cancer must be the platinum-sensitive type, meaning it came back more than 6 months after your last platinum-based chemotherapy ended.
You must have an available genetic test result showing whether your cancer has certain gene changes (BRCA or HRD status) — your doctor can explain what this means for you.
Parts 2 and 3 (Substudies 2 & 3) also require:
You must have a confirmed diagnosis of high-grade serous ovarian, primary peritoneal, or fallopian tube cancer.
Your cancer must have come back after 1 or 2 previous rounds of platinum-based chemotherapy.
Your cancer must be the platinum-sensitive type, meaning it returned more than 6 months after your last platinum-based chemotherapy ended.
Your cancer must be measurable on a scan at the time of joining the trial.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
Part 1 (Substudy 1):
Your cancer got worse while on, or shortly after finishing, your most recent triple-drug treatment course (before joining the trial).
You received an extra dose of a drug called bevacizumab after your last treatment cycle and before joining the trial.
You have previously been treated with a drug called mirvetuximab soravtansine, any other treatment that targets the FRα protein, or a type of drug known as a PARP inhibitor.
Parts 2 and 3 (Substudies 2 & 3):
You have received more than 2 separate courses ("lines") of chemotherapy in the past (confirm with trial site for how your specific treatments are counted, as maintenance therapies and some combined treatments may be counted differently).
You have previously been treated with mirvetuximab soravtansine or any other treatment that targets the FRα protein.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇺 Australia
🇧🇪 Belgium
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇰🇷 South Korea
🇪🇸 Spain
🇺🇸 United States
10 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Substudy 1, 2, and 3: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) (any grade, Grade >= 3); Substudy 1, 2, and 3: Number of Participants with TEAEs Leading to Discontinuation; Substudy 1, 2, and 3: Number of Participants with Ocular Adverse Events (AEs) (any grade, Grade >= 2); Substudy 1, 2, and 3: Overall Response (OR) as Assessed by the Investigator per RECIST v1.1; Substudy 1: Progression free survival (PFS) as Assessed by the Investigator per RECIST v1.1
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.
Analytics cookies are set only if you accept. Advertising runs with personalisation
permanently off and is not changed by this choice — see our
Privacy Policy.